FDA Flags Conflicts for 7-Peptide Panel Members Ahead of Access Review
Updated
Updated · The Washington Post · Jul 17
FDA Flags Conflicts for 7-Peptide Panel Members Ahead of Access Review
3 articles · Updated · The Washington Post · Jul 17
Summary
FDA officials warned that some candidates for a new advisory panel on injectable peptides could pose conflicts of interest because they worked for peptide-related businesses and clinics, according to two people familiar with the matter.
The panel is being assembled under the Trump administration to decide whether the agency should broaden Americans' access to seven injectable peptides that had previously been restricted.
Those restrictions were tied to potential safety concerns, making the panel's composition a key issue as the FDA weighs whether to loosen oversight of the controversial products.